H.C. Wainwright raised the firm’s price target on Tempus AI (TEM) to $98 from $90 and keeps a Buy rating on the shares after the company received 510(k) clearance from the FDA for its updated Tempus Pixel-an AI-power cardiac imaging platform. Tempus Pixel enhances medical imaging by rapidly analyzing scans, highlighting subtle abnormalities, and generating consistent, actionable insights, the analyst tells investors in a research note. H.C. Wainwright believes the enhanced product should help the company achieve “robust and sustainable” growth in the coming quarters.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI Stock (TEM) Rallies as FDA Approves AI Cardiac Imaging Platform
- KLAR, FIG, TEM: Cathie Wood Loads Up on Hot IPO Stocks, Sells Tempus AI
- Tempus AI rises 14.4%
- Tempus AI receives FDA clearance for Tempus Pixel
- Cathie Wood Loads Up on Klarna, Synopsys, and Rubrik, Trims Shopify and Roblox Stocks